









Markets
/
Stocks
/
nasdaq-plur
/

Pluri Inc

PLUR

4.600USD

+0.098+2.18%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

36.31MMarket Cap

LossP/E TTM



Pluri Inc

4.600

+0.098+2.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

141 / 506

Overall Ranking

249 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

12.000

Target Price

+166.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.34M.

Fairly Valued

The company’s latest PE is -1.27, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.98M shares, increasing 9.41% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 27.42K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.98, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 398.00K, representing a year-over-year increase of 314.58%, while its net profit experienced a year-over-year increase of 32.62%.

Score

Industry at a Glance

Previous score

5.98

Change



Financials

4.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.87

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.66

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.24, which is -21.85% below the recent high of -0.97 and -4.76% above the recent low of -1.30.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Pluri Inc is 12.00, with a high of 12.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

12.000

Target Price

+166.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Pluri Inc

PLUR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.06, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.34 and the support level at 3.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.06

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.082

Sell

RSI(14)

44.020

Neutral

STOCH(KDJ)(9,3,3)

33.979

Sell

ATR(14)

0.311

Low Volatility

CCI(14)

-120.013

Sell

Williams %R

71.880

Sell

TRIX(12,20)

-0.208

Sell

StochRSI(14)

31.750

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.718

Sell

MA10

4.786

Sell

MA20

4.969

Sell

MA50

5.013

Sell

MA100

4.922

Sell

MA200

4.719

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 63.33%, representing a quarter-over-quarter increase of 9.08%. The largest institutional shareholder is James Simons, holding a total of 27.42K shares, representing 0.34% of shares outstanding, with 45.07% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Chutzpah Holdings Ltd

1.39M

+0.09%

Merchant Adventure Investment Advisors, LLC

1.28M

Plantae Bioscience Ltd

452.70K

Shayna LP

419.26K

+0.00%

Gunn (John A)

307.25K

Slager (David M)

290.76K

+202.03%

Yanay (Yaky)

260.98K

-34.47%

Regals Capital Management, L.P.

194.49K

+0.06%

Aberman (Zalman)

140.72K

-7.36%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.13, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.